Navigation Links
Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009

NEW YORK, May 27 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. ("Biostar" or the "Company") (OTC Bulletin Board: BSPM) today reported financial results for the three months ended March 31, 2009.

The Company reported revenue of $7,447,664 for the quarter ended March 31, 2009 as compared to $6,810,259 during the first quarter of 2008. Net Income for the first quarter 2009 was $1,829,032, or $0.08 per share on a fully diluted basis, versus $1,821,130, or $0.08 per share, respectively, for 2008.

The increase in revenue reflects an increase in sales for four of Biostar's five state approved drugs. The sales in the four products increased mainly due to the continued implementation of the "Blue Sea" project which markets directly to consumers in the PRC's rural area through retail pharmacies.

Net income did not increase at the same rate as sales did, primarily due to the increase in Selling General and Administrative ("SG&A") expenses as a percentage of sales. SG&A accounted for 33% of sales in the first quarter of 2009 as compared to 30% for the first quarter of 2008, which reflects an increase in staff and marketing budget and expenditure which is expected to benefit the Company's sales effort going forward. This increase in SG&A was partially offset by a decrease in the cost of raw materials, as the Sichuan Province is recovering from the devastating earthquake of 2008, and herbal supplies from the province and their prices have returned to their normal levels.

Ronghua Wang, Chairman and Chief Executive Officer of the Company, stated, "I am pleased that we have been able to report continued growth in revenues as we implement our plans to establish Biostar as a leading provider of over-the-counter and prescription treatments for disease and chronic conditions throughout the People's Republic of China. The investments we are making in marketing, staff and infrastructure will serve us well into the future."

Mr. Wang also commented, "In addition to preparing to commence construction on our new raw materials processing facility, we are completing the planning phase of our 'Mercury Project,' which should commence in the fourth quarter of this year. The Mercury Project targets counties within 31 provinces in the PRC to promote our 'Gan Wang' Compound, our Paracetamol and Amantadine Hydrochloride Capsule -- an over-the-counter drug for the treatment of influenza. As with hepatitis, influenza affects a large portion of the population in the People's Republic of China and there is strong demand for an effective OTC drug to treat the influenza in rural and urban areas."

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in China, develops, manufactures and markets pharmaceutical and medical nutrient products for a variety of diseases and conditions. The Company's most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for Chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based OTC products, two prescription-based pharmaceuticals and ten nutrients. The Company has adopted international standards and is in the process of applying for three patents.

Safe Harbor

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our S-1 dated June 27, 2008, our Quarterly Report on Form 10-Q for the quarters ended September 30, 2008 and March 31, 2009, our 10-K for the year ended December 31, 2008, and other recent filings. These filings are available at . We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

For more information on Biostar Pharmaceuticals, Inc., visit the websites at and .

    For more information, please contact:

    Tel:   +1-866-374-1957 (US)

                          BIOSTAR PHARMACEUTICALS, INC.
                           CONSOLIDATED BALANCE SHEETS

                                                  March 31,      December 31,
                                                   2009              2008
    Current Assets
    Cash and cash equivalents                     $694,645          $758,316
    Accounts receivable                         13,838,976        11,700,841
    Inventories                                    304,605           315,745
    Prepaid expenses and other
     receivables                                 3,324,594         2,926,505
    Total Current Assets                        18,162,820        15,701,407

    Property and equipment, net                  5,845,925         5,930,467

    Intangible assets, net                       7,284,037         7,365,765

    Total Assets                               $31,292,782       $28,997,639


    Current Liabilities
    Accounts payable and accrued expenses       $2,573,483        $2,191,976
    Customer advances                            2,559,308         2,592,250
    Value-added tax payable                        564,814           527,103
    Income tax payable                             480,221           413,205
    Total Current Liabilities                    6,177,826         5,724,534


    Stockholders' Equity
    Series A, convertible preferred
     stock, $0.001 par value, 5,000,000
     shares authorized, none issued and
     outstanding                                        --                --
    Undesignated preferred stock, $.001
     par value, 5,000,000 shares
     authorized,                                        --                --
    Common stock, $.001 par value,
     authorized,23,240,899 shares issued
     and outstanding at March 31, 2009
     and December 31, 2008                          23,241            23,241
    Additional paid-in capital                  10,430,168        10,430,168
    Statutory reserves                           1,776,634         1,585,383
    Retained earnings                           12,634,436        10,996,655
    Accumulated other comprehensive
     income                                        250,477           237,658
    Total Stockholders' Equity                  25,114,956        23,273,105

    Total Liabilities and Stockholders'
     Equity                                    $31,292,782       $28,997,639

                          BIOSTAR PHARMACEUTICALS, INC.

                                                    Three Months Ended
                                                         March 31,
                                                   2009              2008

    Sales, net                                  $7,447,664        $6,810,259

    Cost of sales                                2,658,807         2,638,679

    Gross profit                                 4,788,857         4,171,580

    Selling, general and administrative
     expenses                                    2,479,984         2,052,678

    Income from operations                       2,308,873         2,118,902

    Other Income (Expense)
    Interest income                                    310                79
    Interest expense                                    --           (13,953)
    Total other Income (Expense)                       310           (13,874)

    Income before income taxes                   2,309,183         2,105,028

    Provision for income taxes                     480,151           283,898

    Net income                                  $1,829,032        $1,821,130

    Net income per common share
    Basic                                            $0.08             $0.08
    Diluted                                          $0.08             $0.08

    Weighted average common shares
    Basic                                       23,240,899        22,152,311
    Diluted                                     23,509,458        23,240,899

SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
2. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
3. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
4. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
5. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
6. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
9. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
10. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
11. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, ... and biotechnology industries to improve patient outcomes and quality of life, will now ... testing are being attributed to new regulatory requirements for all new drug products, ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... Md. (PRWEB) , ... October 11, 2017 , ... ... digital pathology, announced today it will be hosting a Webinar titled, “Pathology is ... Advanced Pathology Associates , on digital pathology adoption best practices and how Proscia ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
Breaking Biology Technology:
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
Breaking Biology News(10 mins):